
BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Remidio unveils new device Pristine for innovating AI-powered eye diagnostics

21 May 2025 | News

Pristine sets new benchmark in In-Clinic diagnostics with multi-modality precision and seamless workflow



After a decade of transforming access to eye care in India and beyond, Bengaluru-based Remidio Innovative Solutions has announced a pivotal evolution in its journey, the launch of its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics.

Over the past decade, Remidio has focused on expanding access to eye care. Through portable technology and artificial intelligence (AI), the company has facilitated over 16 million screenings across 40+ countries, addressing low awareness and limited access to early detection. Its Insta series of portable tools for frontline workers has built an ecosystem that now directs millions more patients to ophthalmology clinics annually.

Pristine's suite of in-clinic innovations is built to drive measurable efficiency. Pristine 1.5 reduces retina imaging time per patient through automated workflows. Pristine 5.0 offers true-color, wide-field imaging in seconds, maximizing throughput without compromising quality. The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care. The soon to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.

Together, these devices enable clinics to 'see more, do more', boosting patient volumes, diagnostic confidence, and workflow efficiency.

These platforms are redefining efficiency in clinical ophthalmology, allowing more patients to be seen per day, with better insights, and fewer delays.

With validated AI for Diabetic Retinopathy, Glaucoma, and age-related macular degeneration (AMD), the company is also working on expanding screening capabilities into systemic conditions such as cardiovascular disease (CVD) and chronic kidney disease (CKD), leveraging the eye as a window into overall health. From outreach to in-clinic diagnostics, from retina to systemic health, Remidio's dual brand strategy sets the stage for the next decade of transformation in eye care.